CLINUVEL (ASX:SUV) says it is in late-stage discussions with the European Medicines Agency to increase the recommended maximum number of doses per year of its drug SCENESSE (afamelanotide) for adult patients with erythropoietic protoporphyria.
-
Latest News CLINUVEL says SCENESSE dosage expansion under review by European Medicines Agency November 21, 2024
-
Latest News Opyl signs service level agreement with Southern Clinical Development Consulting November 21, 2024AI-driven clinical trial design and optimisation company Opyl (ASX: OPL) has signed a service-level agreement with Southern Clinical Development Consulting.
-
AusBiotech AusBiotech and MTPConnect bring together life sciences sector for national summit November 19, 2024Today’s National Biotech and Medtech Development and Commercialisation Summit 2024 in Canberra will bring together more than 100 of Australia’s leading industry figures, policy experts, and innovators with the aim of shaping the future of the nation’s biotech and medtech sectors.
-
Latest News CLINUVEL announces plan to prioritise three strategic programs November 19, 2024Australian company CLINUVEL has announced several changes to prioritise its resources towards three critical areas of clinical development.
-
Latest News AdAlta announces appointment of two new non-executive directors November 19, 2024Australian company AdAlta (ASX:1AD) has announced the appointment of two new directors, including experienced industry executives Michelle Burke and Iain Ross.
-
Latest News Radiopharm says targeted therapy demonstrates potential for pancreatic cancer patients November 19, 2024Clinical-stage nuclear medicine company Radiopharm Theranostics (ASX:RAD) has announced the publication of positive results of a retrospective study of the biokinetics of 68Ga-RAD 301 in pancreatic cancer patients.
-
Latest News Neurizon Therapeutics says candidate reduces aggregation of key ALS disease target November 19, 2024Melbourne-based company Neurizon Therapeutics has announced positive results from a preclinical study of its lead candidate, NUZ-001.
-
Latest News Immutep says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data November 14, 2024Clinical-stage company Immutep (ASX:IMM) has announced positive data from the investigator-initiated INSIGHT-003 Phase 1 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer.
-
AusBiotech AusBiotech announces the Inaugural Depaz Oration November 12, 2024AusBiotech has announced the creation of the Depaz Oration, an annual keynote to be introduced at its national conference in 2025 in memory of the late Dr Iris Depaz.
-
Latest News Amplia enters into preclinical collaboration with Korean drug screening company November 14, 2024Amplia Therapeutics (ASX:ATX) has announced that it has entered into a research collaboration with Korean preclinical drug screening company Next&Bio.
-
Latest News AVITA Medical announces distribution agreement to expand to Australia and New Zealand November 14, 2024AVITA Medical (ASX:AVH) has announced it has entered into an exclusive distribution agreement with Revolution Surgical to expand into the Australian and New Zealand markets.
-
Latest News Botanix expands US payer coverage for Sofdra with Ascent Health agreement November 14, 2024Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced that Ascent Health, the second largest Payer organisation in the US, will cover Sofdra (sofpironium) topical gel, 12.45 per cent.
-
Artrya completes successful $5 million placement November 12, 2024The company said the funds will support the ongoing commercialisation of its AI platform that detects critical coronary artery disease imaging markers.
-
Latest News HeraMED completes further $1 million institutional placement November 12, 2024Medical data and technology company HeraMED (ASX:HMD) has received and accepted a further investment offer via a private placement of $1.02 million from three institutional investors.
-
Latest News EMVision says neurodiagnostic algorithms deliver positive results November 12, 2024EMVision Medical Devices (ASX:EMV) has announced positive results for its neurodiagnostic technology to identify stroke and stroke types.
-
Latest News Monash study shows IVF innovation boosts viable embryo selection November 12, 2024Researchers at Monash University have developed a light-emitting microchip that can measure the energy produced by embryos, a key indicator of embryo health.
-
AusBiotech AusBiotech and MTPConnect launch joint discussion paper on critical life science growth issues November 7, 2024AusBiotech and MTPConnect have released a discussion paper ahead of their upcoming National Biotech and Medtech Development and Commercialisation Summit on 19 November 2024 in Canberra.
-
Latest News PYC Therapeutics says first patient dosed in eye disease study November 5, 2024PYC Therapeutics (ASX:PYC) has announced that the first patient with Autosomal Dominant Optic Atrophy (ADOA) has received their first dose of PYC-001.
New Stories
-
Fostering collaboration between our sector and policy makers
November 21, 2024 - - Latest News -
CLINUVEL says SCENESSE dosage expansion under review by European Medicines Agency
November 21, 2024 - - Latest News -
Opyl signs service level agreement with Southern Clinical Development Consulting
November 21, 2024 - - Latest News -
Race Oncology says it has discovered multiple novel FTO inhibitor candidates
November 21, 2024 - - Latest News -
New digital project to reveal medical research career opportunities
November 21, 2024 - - Latest News -
Neurizon Therapeutics says candidate reduces aggregation of key ALS disease target
November 19, 2024 - - Latest News -
AusBiotech and MTPConnect bring together life sciences sector for national summit
November 19, 2024 - - AusBiotech